Literature DB >> 15987290

Poikiloderma of Civatte: a clinical and epidemiological study.

A C Katoulis1, N G Stavrianeas, S Georgala, E Bozi, D Kalogeromitros, E Koumantaki, A D Katsambas.   

Abstract

BACKGROUND: Although a common dermatosis, idiopathic poikiloderma of the face and neck has not been studied in depth for decades.
OBJECTIVES: To reassess the clinical and epidemiological characteristics of poikiloderma of Civatte (PC).
MATERIAL AND METHODS: Fifty consecutive patients with PC. Evaluation included history taking and physical examination. Epidemiological and clinical parameters were recorded and analysed. The literature from 1923 until today, was reviewed thoroughly.
RESULTS: The frequency of PC among dermatologic patients was estimated to be 1.4%. There were 34 females (68%) and 16 males in the present study. The mean age at diagnosis was 47.8 years for females and 61.7 years for males. The majority (88%) had skin phototype II or III. Among females, 26 were at their peri-menopausal stage, including three cases of iatrogenic menopause. Four patients reported that other blood-related family members also had PC. The v and the sides of the neck and the upper chest were most often affected in a symmetric distribution. The face (preauricular and parotid region) was involved in 19 patients (38%). The erythemato-telangiectatic clinical type predominated (58%), followed by the mixed (22%) and the pigmented type (20%). Almost half of the patients (46%) were symptomatic (itching, burning and 'flushing'). The mean duration from onset to diagnosis was 6.2 years according to the patients' report. The course was usually slowly progressive (82%) and irreversible.
CONCLUSIONS: PC shows characteristic features, supporting the theory that it represents a distinct entity. It is rather common in Greece. Although menopausal women predominated in our cohort, men were not uncommonly affected and were diagnosed at an older age. Based on the predominating clinical feature, PC can be classified into three clinical forms. Symmetry and sparing of the anatomically shaded areas of the neck are highly characteristic for PC. Face involvement was not as common and as severe as it had been considered in the past. Recognition of clinical type is important for the selection of the most appropriate treatment, which, despite the advent of novel modalities, remains problematic.

Entities:  

Mesh:

Year:  2005        PMID: 15987290     DOI: 10.1111/j.1468-3083.2005.01213.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  6 in total

Review 1.  Pigmentation Disorders in the Elderly.

Authors:  Andrew M Armenta; Emily D Henkel; Ammar M Ahmed
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

2.  Combination of Specific Vascular Lasers and Vascular Intense Pulsed Light Improves Facial Telangiectasias and Redness.

Authors:  Luigi Bennardo; Cataldo Patruno; Elena Zappia; Federica Tamburi; Mario Sannino; Francesca Negosanti; Steven Paul Nisticò; Giovanni Cannarozzo
Journal:  Medicina (Kaunas)       Date:  2022-05-11       Impact factor: 2.948

Review 3.  Confetti-like Sparing: A Diagnostic Clinical Feature of Melasma.

Authors:  Douglas C Wu; Richard E Fitzpatrick; Mitchel P Goldman
Journal:  J Clin Aesthet Dermatol       Date:  2016-02

4.  The possible role of contact sensitization to fragrances and preservatives in poikiloderma of civatte.

Authors:  Saranya Khunkhet; Penpun Wattanakrai
Journal:  Case Rep Dermatol       Date:  2014-11-14

Review 5.  Acquired hyperpigmentations.

Authors:  Tania Ferreira Cestari; Lia Pinheiro Dantas; Juliana Catucci Boza
Journal:  An Bras Dermatol       Date:  2014 Jan-Feb       Impact factor: 1.896

6.  Poikilodermatous changes on the forearms of a woman practicing aroma-therapy: extracervical poikiloderma of Civatte?

Authors:  Alexandros Katoulis; Michalis Makris; Stamatis Gregoriou; Eustathios Rallis; Antonis Kanelleas; Nicolaos Stavrianeas; Dimitris Rigopoulos
Journal:  An Bras Dermatol       Date:  2014 Jul-Aug       Impact factor: 1.896

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.